Cathay Biotech Revenue vs. Shares Owned By Institutions
| 688065 Stock | 42.02 0.48 1.13% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 2.1 B | Current Value 2.3 B | Quarterly Volatility 229.3 M |
For Cathay Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cathay Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cathay Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cathay Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cathay Biotech over time as well as its relative position and ranking within its peers.
Cathay |
Cathay Biotech Shares Owned By Institutions vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cathay Biotech's current stock value. Our valuation model uses many indicators to compare Cathay Biotech value to that of its competitors to determine the firm's financial worth. Cathay Biotech is rated below average in revenue category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Revenue to Shares Owned By Institutions for Cathay Biotech is about 190,637,950 . At present, Cathay Biotech's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cathay Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cathay Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cathay Revenue vs. Competition
Cathay Biotech is rated below average in revenue category among its peers. Market size based on revenue of Materials industry is presently estimated at about 1.39 Trillion. Cathay Biotech adds roughly 2.11 Billion in revenue claiming only tiny portion of all equities under Materials industry.
Cathay Shares Owned By Institutions vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Cathay Biotech |
| = | 2.11 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Cathay Biotech |
| = | 11.09 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Cathay Shares Owned By Institutions Comparison
Cathay Biotech is currently under evaluation in shares owned by institutions category among its peers.
Cathay Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cathay Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cathay Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Cathay Biotech's change in net profit over the period of time. It can combine multiple indicators of Cathay Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 181.9 M | 134.7 M | |
| Interest Income | 219.8 M | 156.9 M | |
| Operating Income | 273.3 M | 371.7 M | |
| Net Income From Continuing Ops | 408.5 M | 570 M | |
| Income Before Tax | 448.9 M | 471.4 M | |
| Net Income | 366.5 M | 394.3 M |
Cathay Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cathay Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cathay Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cathay Biotech's important profitability drivers and their relationship over time.
Use Cathay Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cathay Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cathay Biotech will appreciate offsetting losses from the drop in the long position's value.Cathay Biotech Pair Trading
Cathay Biotech Pair Trading Analysis
The ability to find closely correlated positions to Cathay Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cathay Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cathay Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cathay Biotech to buy it.
The correlation of Cathay Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cathay Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cathay Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cathay Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cathay Biotech position
In addition to having Cathay Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Single Stock ETFs Thematic Idea Now
Single Stock ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Single Stock ETFs theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Single Stock ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cathay Stock
To fully project Cathay Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cathay Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cathay Biotech's income statement, its balance sheet, and the statement of cash flows.